Session Information
-
WCLC 2018
19th World Conference on Lung Cancer
Conference Program for the 19th World Conference on Lung Cancer in Toronto, Canada
Download PDF of the Abstract Book: Click Here.
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2391
September 23 Sun
Sep 23 Monday
September 24 Mon
Sep 24 Tuesday
September 25 Tue
Sep 25 Wednesday
September 26 Wed
Sep 26
-
+
P3.04 - Immunooncology (Not CME Accredited Session)
- 12:00 - 13:30
- 9/26/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P3.04-01 - Combined Plasma cfDNA Mutations and a Serum Proteomic Signature may Identify Non-Responders to Anti PD-1 Treatment in NSCLC
12:00 - 13:30 | Presenter: Arno Amann | Author(s): Gabriele Gamerith, Alexander Bader, Westen Hahn, Cherie Tschida, Tristin Wolff Cope, Audrey Audetat, Hestia Mellert, Gary Pestano, Heinz Zwierzina
- Abstract
Loading... -
+
P3.04-02 - Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC
12:00 - 13:30 | Presenter: Mark M. Awad | Author(s): Christine A Lydon, Anika Adeni, Safiya Subegdjo, Greg Jones, Vincent Plagnol, John Beeler, Geoffrey R. Oxnard
- Abstract
Loading... -
+
P3.04-03 - Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study
12:00 - 13:30 | Presenter: Marcelo L. Balancin | Author(s): Juliana Machado-Rugolo, Alexandre Todorovic Fabro, Edwin Roger Parras Cuentas, Vanessa Karen De Sá, Claudia Aparecida Rainho, Maria Aparecida Nagai, Vera Luiza Capelozzi
- Abstract
Loading... -
+
P3.04-04 - Prognostic Value of MHC-I, PD-L1 and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer
12:00 - 13:30 | Presenter: Xu Wang | Author(s): Xiao Ding, Jiuwei Cui
- Abstract
Loading... -
+
P3.04-05 - Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
12:00 - 13:30 | Presenter: Zhengwei Dong
- Abstract
Loading... -
+
P3.04-06 - Prognostic Significance of Serum CXCL12 Level in Patients with Surgical Resected Lung Adenocarcinoma
12:00 - 13:30 | Presenter: Jung-Jyh Hung | Author(s): Wen-Hu Hsu
- Abstract
Loading... -
+
P3.04-07 - Correlation Between PD-L1 Expression and Expression of CDK4 and SPOP in Non-Small Cell Lung Cancer
12:00 - 13:30 | Presenter: Masaaki Inoue | Author(s): Junichi Yoshida, Soichi Oka, Yohei Honda, Daisei Yasuda
- Abstract
Loading... -
+
P3.04-08 - Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
12:00 - 13:30 | Presenter: Ticiana A. Leal | Author(s): Jennifer L. Schehr, Alexander Kamisnki, Toby Campbell, Anne Traynor, Joshua M Lang
- Abstract
Loading... -
+
P3.04-09 - Analysis of Repertoire Features of T Cell Receptor in Treat-Naïve EGFR Wild-Type Lung Cancer Patients by High-Throughput Sequencing
12:00 - 13:30 | Presenter: Yangyang Liu | Author(s): Kai Zhang, Wenting Chen, Li Liu
- Abstract
Loading... -
+
P3.04-10 - Monocytes and Neutrophils as Predictive Markers of Response to Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer
12:00 - 13:30 | Presenter: Kaushal Parikh | Author(s): Arun Kumar, Jibran Ahmed, Asad Anwar, Carmelo Puccio, Hoo Chun, Michael Fanucchi, Seah Lim
- Abstract
Loading... -
+
P3.04-11 - The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
12:00 - 13:30 | Presenter: Nir Peled | Author(s): Roxana Denisa Grinberg, Laila C Roisman, Smadar Geva, Martina Lefterova, Katie Quinn, Lior Soussan Gutman, Addie Dvir, Roi Yair, Tal Twito, Richard B Lanman
- Abstract
Loading... -
+
P3.04-12 - Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.
12:00 - 13:30 | Presenter: Domenico Galetta | Author(s): Arsela Prelaj, Pamela Pizzutilo, Michele Montrone, Flavio Cassano, Francesco Pesola, Vittoria Lapadula, Patrizia Petrillo, Nciccolo Varesano, Vito Lamorgese, Angelica Mastrandrea, Donatella Ricci, Annamaria Catino
- Abstract
Loading... -
+
P3.04-13 - PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
12:00 - 13:30 | Presenter: Noemi Reguart | Author(s): Carlos Cabrera, Cristina Aguado, Cristina Teixido, Laia Pare, Josep Castellvi, L. López, Elba Marin, Xana Bernal, Daniel Martinez, Ana Giménez-Capitán, Nuria Vinolas, Zaira Yeste, Nuria Baixeras, Ruth Roman, Miguel-Angel Molina-Vila
- Abstract
Loading... -
+
P3.04-14 - TMB and Immune Checkpoint Inhibitor Gene Expression are Unrelated in NSCLC Patients
12:00 - 13:30 | Presenter: Christopher Wae Keong Szeto | Author(s): Rahul Parulkar, Chad Garner, Sandeep Bobby Reddy
- Abstract
Loading... -
+
P3.04-15 - IDO and Tim3 Gene Expression is Correlated in NSCLC Patients with Low PDL1 Gene Expression
12:00 - 13:30 | Presenter: Christopher Szeto | Author(s): Rahul Parulkar, John Lee, Chad Garner, Sandeep Bobby Reddy
- Abstract
Loading... -
+
P3.04-16 - A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC
12:00 - 13:30 | Presenter: Cristina Teixido | Author(s): Laia Pare, Cristina Aguado, Sandra Lopez, Ana Giménez-Capitán, Andrés F. Cardona, Carlos Cabrera, Sergi Castillo, Mónica Garzón, Clara Mayo, Ivana Sullivan, Silvia Muñoz, Giancarlo Castellano, Pedro Jares, Aleix Prat, Miguel-Angel Molina-Vila, Noemi Reguart
- Abstract
Loading... -
+
P3.04-17 - Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
12:00 - 13:30 | Presenter: Umang Ondhia | Author(s): Henry Conter, Scott Owen, Anna Zhou, Julian Nam, Sumeet Singh, Ahmed Abdulla, Paula Chu, Federico Felizzi, Randeep Sangha
- Abstract
Loading... -
+
P3.04-18 - The Efficacy and Safety of Solid Tumors Combination Therapy with Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis
12:00 - 13:30 | Presenter: YiMing Weng | Author(s): Min Peng, Yi Yao, Qibin Song
- Abstract
Loading... -
+
P3.04-19 - Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis
12:00 - 13:30 | Presenter: Jacques Raphael | Author(s): Anupam Batra, Gabriel Boldt, Prakeshkumar Shah, Phillip Blanchette, George Rodrigues, Mark David Vincent
- Abstract
Loading... -
+
P3.04-20 - Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
12:00 - 13:30 | Presenter: Mike Sung | Author(s): Alona Zer, Preet Walia, Leila Khoja, Manjula Maganti, Catherine Labbe, Frances A Shepherd, Penelope Bradbury, Geoffrey Liu, Natasha B Leighl
- Abstract
Loading... -
+
P3.04-21 - Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer
12:00 - 13:30 | Presenter: Sha Zhao | Author(s): Yijun Jia, Tao Jiang, Xuefei Li, Wei Li, Guanghui Gao, Chao Zhao, Yayi He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou
- Abstract
Loading... -
+
P3.04-22 - Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
12:00 - 13:30 | Presenter: Alessandra Curioni Fontecedro | Author(s): Dilara Akhoundova Sanoyan, Martin Hüllner, Johannes Kraft, Lorenz Bankel, Seok-Yun Lee, Nicolaus Ansratschke
- Abstract
Loading... -
+
P3.04-23 - Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Catherine Shu, Sarah B Goldberg, Vassiliki A Papadimitrakopoulou, Ross Camidge, Sandip Patel, Kristen A. Marrone, Sang-We Kim, Dong-Wan Kim, Hsin-ju Hsieh, Nancy Mueller, Rakesh Kumar, Judson Englert, Keunchil Park
- Abstract
Loading... -
+
P3.04-24 - EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Sue Lee, Paul Curtis, Wilson Caldwell, Bo Gao, Petra Rietschel
- Abstract
Loading... -
+
P3.04-25 - EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50%
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Sue Lee, Paul Curtis, Wilson Caldwell, Bo Gao, Petra Rietschel
- Abstract
Loading... -
+
P3.04-26 - EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Sue Lee, Paul Curtis, Wilson Caldwell, Bo Gao, Petra Rietschel
- Abstract
Loading... -
+
P3.04-27 - An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study
12:00 - 13:30 | Presenter: David S Schrump | Author(s): Mary Zhang, Julie Hong, Tricia Kunst, Colleen Bond, Javier Yeray, Min-Jung Lee, Akira Yuno, Sunmin Lee Lee, Li Xia, Cara Kenney, Cheryl Warga, Tania Guerrero, Taylor Ripley, Chuong Hoang, Sacha Gnjatic, Jeffrey Gildersleeve, Jane Trepel
- Abstract
Loading... -
+
P3.04-28 - Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents?
12:00 - 13:30 | Presenter: Michal Sternschuss | Author(s): Nir Peled, Elizabeth Dudnik, Ofer Rotem, Alona Zer
- Abstract
Loading... -
+
P3.04-29 - Efficacy of Re-Treatment with Immune Checkpoint Inhibitors in Patients with Pretreated Advanced Non-Small Cell Lung Carcinoma
12:00 - 13:30 | Presenter: Takayuki Takahama | Author(s): Masayuki Takeda, Koji Haratani, Kaoru Tanaka, Hidetoshi Hayashi, Kazuhiko Nakagawa
- Abstract
Loading...